Results 81 to 90 of about 18,508 (192)

An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

Future Journal of Pharmaceutical Sciences, 2020
Background A Simple, sensitive, and specific stability indicating reverse phase HPLC method was developed for simultaneous estimation of Lamivudine and Dolutegravir in bulk and tablet dosage form.
Ramreddy Godela, Sowjanya G
doaj   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, Volume 27, Issue 5, Page 803-808, May 2026.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, Volume 27, Issue 5, Page 749-760, May 2026.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source

Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review [PDF]

, 2018
Background: The integrase strand transfer inhibitor dolutegravir (DTG) is being introduced into low- and middle-income countries (LMICs) as an alternative to first-line treatment with non-nucleoside reverse transcriptase inhibitors.
Christie, R, Clayden, P, Hill, A, Thorne, C, Zash, R   +4 more
core  

Perinatal and early infant outcomes after first‐versus second‐generation integrase strand transfer inhibitor use in pregnancy

HIV Medicine, Volume 27, Issue 5, Page 761-770, May 2026.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Rosa Balleny, Jeffrey Man Hay Wong, Terry Lee, Ari Bitnun, Isabelle Boucoiran, Jason Brophy, Jeannette Comeau, Fatima Kakkar, Athena McConnell, Laura Sauvé, Joel Singer, Alena Tse‐Chang, Deborah Money   +12 more
wiley   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source

Dosing antiretroviral medication when crossing time zones: a review [PDF]

, 2016
International tourism continues to increase worldwide, and people living with HIV and their clinicians are increasingly confronted with the problem of how to dose antiretroviral therapy during transmeridian air travel across time zones.
Boffito, Marta, Khoo, Saye, Lewis, Joseph M, Volny-Anne, Alain, Waitt, Catriona   +4 more
core   +1 more source

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study [PDF]

, 2017
BACKGROUND: There is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries.
Apollo, T, Bertagnolio, S, Cambiano, V, De Luca, A, Doherty, M, Hallett, TB, Havlir, D, Jordan, MR, Kuritzkes, DR, Lundgren, JD, Mellors, J, Mhangara, M, Nakagawa, F, Nichols, B, Parikh, U, Phillips, AN, Pillay, D, Pozniak, A, Raizes, E, Revill, P, Rinke de Wit, T, Sigaloff, K, van de Vijver, D, Vitoria, M, Wainberg, MA, Working Group on Modelling Potential Responses to High Levels of, .   +25 more
core  

Prevalence and Correlates of Hyperglycemia Among People Living With HIV and TB on Dolutegravir‐Based Antiretroviral Therapy in Zimbabwe: A Cross‐Sectional Study

Health Science Reports
Background and Aims In low‐ and middle‐income countries, dolutegravir‐based antiretroviral therapy regimens are the preferred first‐line treatment for adults, adolescents, and children with human immunodeficiency virus (HIV).
Tafadzwa Zireva, Cuthbert Musarurwa, Arthur Mazhandu, Brenda Nherera, Shungu Munyati, Justen Manasa, Danai Tavonga Zhou, Donald Vhanda   +7 more
doaj   +1 more source